How is enablement evaluated for compound or composition claims limited by a particular use?

For compound or composition claims limited by a particular use, enablement should be evaluated based on that specific limitation. The MPEP provides guidance on this: When a compound or composition claim is limited by a particular use, enablement of that claim should be evaluated based on that limitation. (MPEP 2164.01(c)) This approach ensures that the…

Read More

What is the significance of the Enzo Biochem v. Calgene case in patent enablement?

The Enzo Biochem v. Calgene case is significant in patent enablement because it illustrates how courts assess the scope of enablement in biotechnology patents. The MPEP Section 2164.06(b) summarizes the case: “The court held that two patents with claims directed to genetic antisense technology (which aims to control gene expression in a particular organism), were…

Read More

Can a patent specification be enabling without describing the invention?

Yes, it is possible for a patent specification to be enabling without fully describing the invention. The MPEP 2161 provides an example of this situation: “A disclosure could be enabling without describing the invention (e.g., a specification describing a method of making and using a paint composition made of functionally defined ingredients within broad ranges…

Read More

How does the enablement requirement apply to unstable or transitory chemical intermediates?

For unstable and transitory chemical intermediates, the enablement requirement is applied differently. According to MPEP 2164.01(b), “for unstable and transitory chemical intermediates, the ‘how to make’ requirement does not require that the applicant teach how to make the claimed product in stable, permanent or isolatable form.” This principle was established in the case of In…

Read More